Cover Image
市場調查報告書

體外診斷 (IVD) 的全球市場:市場機會與預測 (2015∼2022年)

World In Vitro Diagnostics - Market Opportunities and Forecasts, 2015 - 2022

出版商 Allied Market Research 商品編碼 354609
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
體外診斷 (IVD) 的全球市場:市場機會與預測 (2015∼2022年) World In Vitro Diagnostics - Market Opportunities and Forecasts, 2015 - 2022
出版日期: 2016年02月01日 內容資訊: 英文 120 Pages
簡介

全球體外診斷 (IVD) 市場,預共2022年以2.9%的年複合成長率擴大,達到813億美元。慢性疾病和感染疾病的罹患率上升,容易得到免疫疾病的老年人增加等,使體外診斷檢驗的需求增大。再加上個人化醫療的擴展和罕見疾病的知識擴大拉抬市場成長。

本報告提供全球體外診斷 (IVD) 市場現狀與至2022年的成長預測,各產品、各技術、各用途、各終端用戶,及各地區趨勢,以及市場趨勢與課題,以及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 法律規章
  • 價值鏈分析
  • 案例研究
  • 研究及分析
  • 體外診斷技術中的大進步
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 全球體外診斷市場:各產品

  • 概要
  • 試劑
  • 設備
  • 軟體及服務

第5章 全球體外診斷市場:各技術

  • 免疫診斷
  • 血液檢驗
  • 分子診斷
  • 組織診斷
  • 臨床化學
  • 其他臨床技術

第6章 全球體外診斷市場:各用途

  • 感染疾病
  • 癌症
  • 心臟病
  • 免疫系疾病
  • 神經疾病
  • 腸胃疾病
  • 其他

第7章 全球體外診斷市場:各終端用戶

  • 獨立的實驗室
  • 醫院
  • 學術機構、醫療學校
  • 其他

第8章 全球體外診斷市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第9章 企業簡介

  • Affymetrix Inc.
  • Alere Inc.
  • Biomerieux
  • Danaher Corporation.
  • Roche Diagnostics
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • Bayer AG.
  • Arkray, Inc.
  • Sysmex Corporation
  • Johnson & Johnson Pvt Ltd.
  • Siemens AG

圖表

目錄
Product Code: LI 15286

Title: World In Vitro Diagnostics (IVD) Market by Techniques (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, IVD Techniques), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases) and End Users (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care) - Global Opportunity Analysis and Industry Forecast, 2015 - 2022.

In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues and other body fluids, which are derived from the human body to detect diseases, conditions and infections. The tests can be performed in stand-alone laboratory, hospital based laboratory and point of care. Some of the significant technologies incorporated in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry, which are used for test sample preparation. Incessant innovations in IVD product design and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.

The world in vitro diagnostics market is estimated to garner $81.3 billion by 2022, registering a CAGR of 4.9% over the forecast period. Growing need of IVD testing arises due to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders. Moreover, increased application of personalised medicines and widespread knowledge of rare diseases are boosting the growth of IVD market. In addition, increasing incidences of colorectal cancer, neurological disorders, gynaecological diseases and others would boost the adoption of IVD devices and reagents. On the contrary, stringent government regulations and unfavourable reimbursement policies would limit the growth of the market. The rising demand for technologically advanced diagnostic devices and increased disposable income of consumers provides huge growth potential for IVD market.

The report segments the market across different categories such as product type, techniques, application, end users and geography. Based on product types, the market is segmented into reagents, instruments, and services & software. Based on techniques, the market is segmented into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry and other clinical techniques. Similarly, based on indication, the market is further segmented into, infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal disorders and other indications. Based on end users, the market is categorised into standalone laboratory, hospitals academics & medical schools and others. The geographical breakdown and detailed analysis of each of the aforesaid segments are included for North America, Europe, Asia-Pacific and LAMEA.

Companies are adopting acquisition and partnership as key development strategies in this market Roche diagnostics, Abbott, Danaher Corporation are few of the dominant players in the IVD market. Other companies include Johnson and Johnson, Sysmex Corporation, Becton Dickinson, bioMrieux, Thermo Fisher Scientific, Inc., Ortho-Clinical Diagnostics, Siemens AGand Alere Inc. The comprehensive competitive analysis and profiles of major market players mentioned above are profiled in the report.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an extensive analysis of the current and emerging trends and dynamics in the world IVD market.

Geographically, the world IVD market is analyzed based on various regions such as North America, Europe, Asia-Pacific and LAMEA.

This report entails the detailed quantitative analysis of the current market and estimations from 2015 to 2022, which assists in identifying the prevailing market opportunities.

Exhaustive analysis of the world IVD market by techniques helps in understanding the variants of IVD testing techniques that will gain prominence in the future.

Competitive intelligence highlights the business practices followed by leading market players across various geographies.

SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.

IVD MARKET KEY SEGMENTS:

By Product type

  • Reagents
  • Instruments,
  • Software & Services

By Techniques

  • Immunodiagnostics
  • Blood Testing
  • Molecular Diagnostics
  • Tissue Diagnostics
  • Clinical Chemistry
  • Other Clinical Techniques

By Application

  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Other Indications

By End Users

  • Standalone Laboratory
  • Hospitals
  • Academic & Medical Schools
  • Others

By Geography

  • North America
    • Canada
    • U.S
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Others
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • Others
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond: what to expect by 2027
    • 2.2.1. Base case scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
    • 3.2.3. Top winning strategies
  • 3.3. Porter five forces analysis
    • 3.3.1. Bargaining power of supplier
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Low threat of new entrants
    • 3.3.4. Threat of substitute
    • 3.3.5. Competitive rivalry
  • 3.4. Government regulations
  • 3.5. Value chain analysis
  • 3.6. Case studies
    • 3.6.1. Case Study 1: Positioning of new IVD Platform by Life Science
    • 3.6.2. Case Study 2: To enhance the operational capabilities of diagnostic chemistry system
  • 3.7. Research & Analysis
    • 3.7.1. Clinical Trials of research studies conducted for IVD market
  • 3.8. Significant Progressions in IVD technologies
    • 3.8.1. Total Laboratory Automation (TLA)
    • 3.8.2. Evolving markets in digital pathology
    • 3.8.3. Omics and Genetics tests in IVD
    • 3.8.4. Point-of-Care testing
    • 3.8.5. Emerging technologies diagnostics and influence on IVD
  • 3.9. Market dynamics
    • 3.9.1. Drivers
      • 3.9.1.1. Increasing incidences of chronic and infectious diseases
      • 3.9.1.2. Technological advancements in IVD
      • 3.9.1.3. Emergence of minimal invasive technologies
      • 3.9.1.4. Increasing government expenditures on healthcare
      • 3.9.1.5. Increase in popularity personalized medicine approach
    • 3.9.2. Restraints
      • 3.9.2.1. Unclear reimbursement policies
      • 3.9.2.2. Stringent Regulatory policies
    • 3.9.3. Opportunities
      • 3.9.3.1. Potential Opportunities for outsourcing
      • 3.9.3.2. Convergence of new Technologies.

CHAPTER 4: WORLD IVD MARKET, BY PRODUCT TYPE, 2014-2022

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Reagents
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Instruments
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. Software and services
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast

CHAPTER 5: WORLD IVD MARKET, BY TECHNIQUES, 2014-2022

  • 5.1. Immunodiagnostics
    • 5.1.1. Key market trends
    • 5.1.2. Key growth factors and opportunities
    • 5.1.3. Market size and forecast
  • 5.2. Blood testing
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
  • 5.3. Molecular diagnostics
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
  • 5.4. Tissue diagnostics
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
  • 5.5. Clinical chemistry
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
  • 5.6. Other clinical techniques
    • 5.6.1. Key market trends
    • 5.6.2. Key growth factors and opportunities
    • 5.6.3. Market size and forecast

CHAPTER 6: WORLD IVD MARKET, BY APPLICATION, 2014-2022

  • 6.1. Infectious diseases
    • 6.1.1. Key market trends
    • 6.1.2. Key growth factors and opportunities
    • 6.1.3. Market size and forecast
  • 6.2. Cancer
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast
  • 6.3. Cardiac diseases
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast
  • 6.4. Immune system diseases
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast
  • 6.5. Nephrological diseases
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast
  • 6.6. Gastrointestinal diseases
    • 6.6.1. Key market trends
    • 6.6.2. Key growth factors and opportunities
    • 6.6.3. Market size and forecast
  • 6.7. Other indications
    • 6.7.1. Key market trends
    • 6.7.2. Key growth factors and opportunities
    • 6.7.3. Market size and forecast

CHAPTER 7: WORLD IVD MARKET BY END USERS, 2014-2022

  • 7.1. Standalone laboratories
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast
  • 7.3. Academic and medical schools
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast
  • 7.4. Others
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast

CHAPTER 8: WORLD IVD MARKET BY GEOGRAPHY, 2014-2022

  • 8.1. North America
    • 8.1.1. Key market trends
    • 8.1.2. Key growth factors and opportunities
    • 8.1.3. Market size and forecast
    • 8.1.4. United states
      • 8.1.4.1. Market size and forecast
    • 8.1.5. Canada
      • 8.1.5.1. Market size and forecast
    • 8.1.6. Mexico
      • 8.1.6.1. Market size and forecast
  • 8.2. Europe
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast
    • 8.2.4. Germany
      • 8.2.4.1. Market size and forecast
    • 8.2.5. France
      • 8.2.5.1. Market size and forecast
    • 8.2.6. United Kingdom
      • 8.2.6.1. Market size and forecast
    • 8.2.7. Others
      • 8.2.7.1. Market size and forecast
  • 8.3. Asia Pacific
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast
    • 8.3.4. India
      • 8.3.4.1. Market size and forecast
    • 8.3.5. China
      • 8.3.5.1. Market size and forecast
    • 8.3.6. Japan
      • 8.3.6.1. Market size and forecast
    • 8.3.7. Australia
      • 8.3.7.1. Market size and forecast
    • 8.3.8. Others
      • 8.3.8.1. Market size and forecast
  • 8.4. LAMEA
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
    • 8.4.4. Latin America
      • 8.4.4.1. Market size and forecast
    • 8.4.5. Middle East
      • 8.4.5.1. Market size and forecast
    • 8.4.6. Africa
      • 8.4.6.1. Market size and forecast

CHAPTER 9: COMPANY PROFILES

  • 9.1. Affymetrix Inc.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Financial performance of Affymetrix Inc.
    • 9.1.4. Key Strategies and development
    • 9.1.5. SWOT analysis of Affymetrix
  • 9.2. Alere Inc.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Business performance
    • 9.2.4. Key strategies and developments
    • 9.2.5. SWOT analysis of Alere
  • 9.3. Biomerieux
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Business performance
    • 9.3.4. Key strategies and developments
    • 9.3.5. SWOT analysis of BioMerieux
  • 9.4. Danaher Corporation.
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Business performance
    • 9.4.4. Key strategies and development
    • 9.4.5. SWOT analysis of Danaher Corporation
  • 9.5. Roche Diagnostics
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Business performance
    • 9.5.4. Key strategies and developments
    • 9.5.5. SWOT analysis of Roche Diagnostics
  • 9.6. Becton Dickinson and Company
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Business performance
    • 9.6.4. Key strategies and development
    • 9.6.5. SWOT analysis of Becton Dickinson and Company
  • 9.7. Bio-Rad Laboratories, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Business performance
    • 9.7.4. Key strategies and developments
    • 9.7.5. SWOT analysis of Bio-Rad Laboratories, Inc.
  • 9.8. Abbott Laboratories
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Business performance
    • 9.8.4. Key strategies and developments
    • 9.8.5. SWOT analysis of Abbott Laboratories
  • 9.9. Bayer AG.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Business performance
    • 9.9.4. Key strategies and development
    • 9.9.5. SWOT analysis of Bayer AG
  • 9.10. Arkray, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Key strategies and development
    • 9.10.4. SWOT analysis of Arkray, Inc.
  • 9.11. Sysmex Corporation
    • 9.11.1. Company overview
    • 9.11.2. Company snapshot
    • 9.11.3. Business performance
    • 9.11.4. Key strategies and developments
    • 9.11.5. SWOT analysis of Sysmex Corporation
  • 9.12. Johnson & Johnson Pvt Ltd.
    • 9.12.1. Company overview
    • 9.12.2. Company snapshot
    • 9.12.3. Business performance
    • 9.12.4. Key strategies and development
    • 9.12.5. SWOT analysis of Johnson & Johnson Pvt Ltd.
  • 9.13. Siemens AG
    • 9.13.1. Company overview
    • 9.13.2. Company snapshot
    • 9.13.3. Business performance
    • 9.13.4. Key strategies and development
    • 9.13.5. SWOT analysis of Siemens AG

List of Tables

  • TABLE 1: WORLD IVD BASE CASE SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
  • TABLE 2: WORLD IVD RAPID GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
  • TABLE 3: WORLD IVD DIMINISHING GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
  • TABLE 4: PORTERS FIVE FORCES ANALYSIS
  • TABLE 5: CLINICAL TRIALS - IN VITRO DIAGNOSTIC DEVICES
  • TABLE 6: GLOBAL INCIDENCES OF DISEASES
  • TABLE 7: WORLD IVD MARKET, BY PRODUCT TYPE, 2014-2022 ($MILLION)
  • TABLE 8: WORLD IVD REAGENTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 9: WORLD IVD INSTRUMENTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 10: WORLD IVD SOFTWARE AND SERVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11: WORLD IVD MARKET BY TECHNIQUE, 2014-2022 ($MILLION)
  • TABLE 12: WORLD IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 13: WORLD IVD BLOOD TESTING TECHNIQUE MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 14: WORLD IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 15: WORLD IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, 2014-2022, ($MILLION)
  • TABLE 16: WORLD IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 17: WORLD IVD OTHER CLINICAL TECHNIQUES MARKET, BY GEOGRAPHY, 2014-2022, ($MILLION)
  • TABLE 18: WORLD IVD MARKET, BY INDICATION, 2014-2022 ($MILLION)
  • TABLE 19: WORLD IVD INFECTIOUS DISEASES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 20: WORLD IVD CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 21: WORLD IVD CARDIAC DISEASES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 22: WORLD IVD IMMUNE SYSTEM DISORDER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 23: WORLD IVD NEPHROLOGICAL DISEASES MARKET, BY GEOGRAPHY, 2014-2022, ($MILLION)
  • TABLE 24: WORLD IVD GASTRINTESTINAL DISEASES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 25: WORLD IVD OTHER INDICATION MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 26: WORLD IVD MARKET, BY END USER, 2014-2022, ($MILLION)
  • TABLE 27: WORLD IVD STANDALONE LABORATORIES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 28: WORLD IVD HOSPITALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 29: WORLD IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY GEOGRAPHY, 2014- 2022 ($MILLION)
  • TABLE 30: WORLD IVD OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 31: WORLD IVD MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 32: NORTH AMERICA IVD MARKET, BY TECHNIQUES, 2014-2022 ($MILLION)
  • TABLE 33: UNITED STATES IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 34: CANADA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 35: MEXICO IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 36: EUROPE IVD MARKET, BY TECHNIQUES, 2014-2022 ($MILLION)
  • TABLE 37: GERMANY IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 38: FRANCE IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 39: UNITED KINGDOM IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 40: OTHERS EUROPEAN IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 41: ASIA PACIFIC IVD MARKET, BY TECHNIQUES, 2014-2022 ($MILLION)
  • TABLE 42: INDIA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 43: CHINA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 44: JAPAN IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 45: CATEGORIZATION OF IVD DEVICES
  • TABLE 46: AUSTRALIA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 47: OTHERS IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 48: LAMEA IVD MARKET, BY TECHNIQUES, 2014-2022 ($MILLION)
  • TABLE 49: LATIN AMERICA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 50: MIDDLE EAST IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 51: AFRICA IVD MARKET REVENUE, BY TECHNIQUES, 2014-2022, ($MILLION)
  • TABLE 52: COMPANY SNAPSHOT OF AFFYMETRIX INC.
  • TABLE 53: ALERE INC. COMPANY SNAPSHOT
  • TABLE 54: BIOMERIEUX COMPANY SNAPSHOT
  • TABLE 55: DANAHER CORPORATION COMPANY SNAPSHOT
  • TABLE 56: ROCHE DIAGNOSTICS COMPANY SNAPSHOT
  • TABLE 57: BECTON DICKINSON AND COMPANY SNAPSHOT
  • TABLE 58: BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
  • TABLE 59: ABBOTT LABORATORIES SNAPSHOT
  • TABLE 60: BAYER AG COMPANY SNAPSHOT
  • TABLE 61: ARKRAY, INC. COMPANY SNAPSHOT
  • TABLE 62: SYSMEX CORPORATION COMPANY SNAPSHOT
  • TABLE 63: JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT
  • TABLE 64: SIEMENS AGCOMPANY SNAPSHOT

List of Figures

  • FIG. 1: WORLD IVD MARKET SNAPSHOT
  • FIG. 1: TOP IMPACTING FACTORS, BASE CASE SCENARIO (2022-2027)
  • FIG. 2: TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)
  • FIG. 3: TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)
  • FIG. 4: TOP IMPACTING FACTORS
  • FIG. 5: TOP INVESTMENT POCKETS OF IVD MARKET BY TECHNIQUES 2014-2022.
  • FIG. 6: TOP WINNING STRATEGIES
  • FIG. 7: TOP WINNING STRATEGIES
  • FIG. 8: VALUE CHAIN ANALYSIS FOR IVD MARKET
  • FIG. 9 : EY FINANCIALS OF AFFYMETRIX INC. REVENUE, 2012-2014, $MILLION
  • FIG. 10: KEY FINANCIALS OF AFFYMETRIX INC. REVENUE BY SEGMENTS
  • FIG. 11: KEY FINANCIALS OF AFFYMETRIX INC.CORPORATION REVENUE BY GEOGRAPHY
  • FIG. 12: SWOT ANALYSIS OF AFFYMETRIX INC.
  • FIG. 13: KEY FINANCIALS OF ALERE INC. REVENUE, 2012-2014, $MILLION
  • FIG. 14: ALERE INC., % NET SALES BY BUSINESS SEGMENTS, 2014
  • FIG. 15: ALERE INC., % NET SALES BY GEOGRAPHY, 2014
  • FIG. 16: SWOT ANALYSIS OF ALERE INC.
  • FIG. 17: KEY FINANCIALS OF BIOMERIEUX REVENUE, 2011-2014, $MILLION
  • FIG. 18: BIOMERIEUX, % NET SALES BY TECHNOLOGY, 2014
  • FIG. 19: BIOMERIEUX, % NET SALES BY GEOGRAPHY, 2014
  • FIG. 20: SWOT ANALYSIS OF BIOMERIEUX
  • FIG. 21: DANAHER CORPORATION, % NET SALES BY BUSINESS SEGMENT, 2014
  • FIG. 22: DANAHER CORPORATION, % NET SALES BY GEOGRAPHY, 2014
  • FIG. 23: SWOT ANALYSIS OF DANAHER CORPORATION
  • FIG. 24: KEY FINANCIALS OF ROCHE DIAGNOSTICS REVENUE, 2012-2014, $MILLION
  • FIG. 25: ROCHE DIAGNOSTICS, % NET SALES BY BUSINESS SEGMENT, 2014
  • FIG. 26: ROCHE DIAGNOSTICS, % NET SALES BY GEOGRAPHY, 2014
  • FIG. 27: SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIG. 28: KEY FINANCIALS OF BECTON, DICKINSON AND COMPANY REVENUE, 2011-2014, $MILLION
  • FIG. 29: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY REVENUES BY SEGMENT 2014
  • FIG. 30: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY SALES BY GEOGRAPHY 2014
  • FIG. 31: SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
  • FIG. 32: KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUE, 2012-2014, $MILLION
  • FIG. 33: BIO RAD LABORATORIES, INC., % REVENUE BY BUSINESS SEGMENT, 2014
  • FIG. 34: BIO RAD LABORATORIES, INC., % REVENUE BY GEOGRAPHY, 2014
  • FIG. 35: SWOT ANALYSIS OF BIO-RAD LABORATORIES, INC.
  • FIG. 36: KEY FINANCIALS OF ABBOTT LABORATORIES REVENUE, 2012-2014, $MILLION
  • FIG. 37: ABBOTT LABORATORIES, INC., % REVENUE BY BUSINESS SEGMENT, 2014
  • FIG. 38: ABBOTT LABORATORIES, INC., % REVENUE BY GEOGRAPHY, 2014
  • FIG. 39: SWOT ANALYSIS OF ABBOTT LABORATORIES
  • FIG. 40: KEY FINANCIALS OF ABBOTT LABORATORIES REVENUE, 2012-2014, $MILLION
  • FIG. 41: BAYER AG, % REVENUE BY BUSINESS SEGMENT, 2014
  • FIG. 42: SWOT ANALYSIS OF BAYER AG
  • FIG. 43: SWOT ANALYSIS OF ARKRAY, INC.
  • FIG. 44: KEY FINANCIALS OF SYSMEX CORPORATION REVENUE, 2012-2014, $MILLION
  • FIG. 45: SYSMEX CORPORATION, % REVENUE, BY BUSINESS SEGMENT, 2014
  • FIG. 46: SYSMEX CORPORATION, % REVENUE, BY PRODUCT TYPE, 2014
  • FIG. 47: SYSMEX CORPORATION, % REVENUE BY GEOGRAPHY, (2014)
  • FIG. 48: SWOT ANALYSIS OF SYSMEX CORPORATION
  • FIG. 49: KEY FINANCIALS OF JOHNSON & JOHSNON $MILLION (2012-2014)
  • FIG. 50: FINANCIAL REVENUES BY SEGMENTS (2014)
  • FIG. 51: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 52: SWOT ANALYSIS OF JOHNSON & JOHNSON PVT LTD.
  • FIG. 53:
  • FIG. 54: SIEMENS AG., % REVENUE BY BUSINESS SEGMENT, 2014
  • FIG. 55: SIEMENS AG., % REVENUE BY GEOGRAPHY, 2014
  • FIG. 56: SWOT ANALYSIS OF SIEMENS AG
Back to Top